Skip to main content

Table 2 Patients' classification according Immune response

From: Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients

Study Patients' classification Anti EGF antibody titers
(Geometric mean of sera dilution)
  GAR SGAR  
Phase II Trial
(low dose, 1 injection site)
18 (52.8%) 4 (10.8%) 1:3160
Phase III trial
(high dose, 4 injection sites)
22 (56.4%) 12 (30.8%) 1:7328
  1. Patients were classified as Good Antibody Responders (GAR) if they reached an anti-EGF antibody titer ≥ 1:4000 and SGAR if they reached an anti-EGF antibody titer ≥ 1:64000.
\